Patients in remission of lymphoma at time of T-cell infusion
| UPN . | Age, y/sex . | Disease (stage at diagnosis) . | No. of relapses . | Most recent treatment (time before CTL infusion) . | Total CTL dose, m−2 . | Response to CTL infusion (survival mo) . |
|---|---|---|---|---|---|---|
| 7 | 66/F | Diffuse large B-cell NHL stage IIa | 3 | Auto SCT-BEAM-R (3 mo) | 4 × 107 | Remains in remission (> 37 mo) |
| 8 | 57/F | Diffuse large B-cell NHL stage IVb | 2 | Auto SCT-BEAM-R (5 mo) | 4 × 107 | NR (died 22 mo) |
| 9 | 50/F | Mixed cellularity HD stage IIIa | 4 | Liposomal vincristine (6 mo) | 4 × 107 | Remains in remission (died secondary MDS 20 mo) |
| 10 | 25/F | Nodular sclerosing HD stage IIa | 1 | Auto SCT-BU/Mel/thiotepa (10 mo) | 1.2 × 108 | Remains in remission (> 24 mo) |
| 11 | 30/M | Nodular sclerosing HD stage IIb | 4 | ABVD (7 mo) | 1.2 × 108 | Remains in remission (> 23 mo) |
| 12 | 59/M | Nodular sclerosing HD stage IIb | 1 | Auto SCT-BEAM (4 mo) | 1.2 × 108 | Remains in remission (> 6 mo) |
| 13 | 51/M | NK/T-cell NHL (nasal) | 0 | RT (1 mo) | 1.2 × 108 | Remains in remission (6 mo) |
| 14 | 60/F | NK/T-cell NHL | 0 | COP (1 mo) | 1.2 × 108 | Remains in remission (3 mo) |
| 15 | 37/M | NK/T-cell NHL | 0 | CHOP and RT (3 mo) | 1.2 × 108 | Remains in remission (8 wk) |
| 16 | 7/M | Mixed cellularity HD stage Ia (after lung transplantation) | 0 | Rituximab (8 mo) | 3 × 108 | Remains in remission (> 18 mo) |
| UPN . | Age, y/sex . | Disease (stage at diagnosis) . | No. of relapses . | Most recent treatment (time before CTL infusion) . | Total CTL dose, m−2 . | Response to CTL infusion (survival mo) . |
|---|---|---|---|---|---|---|
| 7 | 66/F | Diffuse large B-cell NHL stage IIa | 3 | Auto SCT-BEAM-R (3 mo) | 4 × 107 | Remains in remission (> 37 mo) |
| 8 | 57/F | Diffuse large B-cell NHL stage IVb | 2 | Auto SCT-BEAM-R (5 mo) | 4 × 107 | NR (died 22 mo) |
| 9 | 50/F | Mixed cellularity HD stage IIIa | 4 | Liposomal vincristine (6 mo) | 4 × 107 | Remains in remission (died secondary MDS 20 mo) |
| 10 | 25/F | Nodular sclerosing HD stage IIa | 1 | Auto SCT-BU/Mel/thiotepa (10 mo) | 1.2 × 108 | Remains in remission (> 24 mo) |
| 11 | 30/M | Nodular sclerosing HD stage IIb | 4 | ABVD (7 mo) | 1.2 × 108 | Remains in remission (> 23 mo) |
| 12 | 59/M | Nodular sclerosing HD stage IIb | 1 | Auto SCT-BEAM (4 mo) | 1.2 × 108 | Remains in remission (> 6 mo) |
| 13 | 51/M | NK/T-cell NHL (nasal) | 0 | RT (1 mo) | 1.2 × 108 | Remains in remission (6 mo) |
| 14 | 60/F | NK/T-cell NHL | 0 | COP (1 mo) | 1.2 × 108 | Remains in remission (3 mo) |
| 15 | 37/M | NK/T-cell NHL | 0 | CHOP and RT (3 mo) | 1.2 × 108 | Remains in remission (8 wk) |
| 16 | 7/M | Mixed cellularity HD stage Ia (after lung transplantation) | 0 | Rituximab (8 mo) | 3 × 108 | Remains in remission (> 18 mo) |
For all patients, there was no toxicity attributed to CTL infusion.
UPN indicates unique patient number; BEAM/BEAM-R, BCNU, etoposide, cytarabine, melphalan ± rituximab; MDS, myelodysplastic syndrome; SCT, stem cell transplantation; BU, busulfan; MEL, melphalan; ABVD, doxorubicin, bleomycin, vinblastine and dacarbazine; RT, radiotherapy; and COP, cyclophosphamide, vincristine and prednisone.